A Phase 4 interventional study of Oral Acetazolamide and Placebo in Acute Decompensated Heart Failure, sponsored by Universitas Diponegoro. Recruiting at 2 sites in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-22.
Sponsored by Universitas Diponegoro · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing acetazolamide in Heart Failure — 6 open to participants now, 7 under way, 2 of them phase 3. Acetazolamide · Heart Failure.
Among the 14 studies testing acetazolamide in Heart Failure, this one is the 7th largest by planned enrollment, is one of 4 that started in 2024, is one of 8 in phase 4, and was the 10th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 14 studies testing acetazolamide in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Johannes Grand · Sites in Denmark
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
Lucrecia Maria Burgos
Ages 18+
Clinica Alemana de Santiago
Ages 18+
By country, each count listing its studies:
Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 14 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Universitas Diponegoro is the lead sponsor of 23 studies on the registry; 11 are open to participants now.
Universitas Diponegoro has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies testing acetazolamide in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593612Lucrecia Maria BurgosTACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart Failure | 2027-01-15 |
| NCT07372040Tanta UniversityAdd-on Diuretics in Acute Decompensated Heart Failure | 2027-02-01 |
| NCT06273397Clinica Alemana de SantiagoAcetazolamide or Metolazone in Acute Heart Failure | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing acetazolamide in Heart Failure, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Based on ADVOR trial, the potential of adding acetazolamide in increasing the success of decongestion, the amount of natriuresis and diuresis. However, the use of intravenous acetazolamide may not be possible in Indonesia, where the intravenous formulation is not available. This clinical research study is being conducted in single hospitals in Indonesia. We aim to learn if Oral Acetazolamide in addition to Furosemide intravenous works to treat congestion in Acute Decompensated Heart Failure, besides evaluating the total urinary output, change of NT pro BNP level, and safety profile of oral Acetazolamide.
The hypothesis of this study is oral acetazolamide works well to achieve successful decongestion.
This is a randomized, double blind study with 2 treatment groups. Participants diagnosed with ADHF who meet the inclusion criteria and no exclusion criteria are given an explanation regarding the research and additional therapy that will be given, then informed consent is requested. Participants will be randomized to one of the two treatment groups by chance. Patients randomized to the first group will receive intravenous furosemide and oral acetazolamide. Patients randomized to the other treatment group will receive a combination of iv furosemide and placebo. It is expected that the patients of the treatment group with the combination therapy will have a faster reduction of their fluid overload. In consequence the treatment duration and total dose of diuretics administered will be shorter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received intravenous furosemide plus acetazolamide 250 mg / 12 hours orally for up to 3 days.
Drug: Oral Acetazolamide
Participants who received intravenous furosemide plus Placebo / 12 hours orally for up to 3 days.
Drug: Placebo
Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
Also known as: Glauseta
Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
Successful Decongestion
Conditions without volume overload, no signs of excess volume within 3 days of treatment. Congestion was assessed using the volume assessment score (also called congestion score) from the ADVOR trial. The absence of fluid volume excess was defined as no more than mild edema, no residual pleural effusion, and no residual ascites. Total score ≤1 indicates that decongestion has been achieved, score \>1 is considered to indicate persistent fluid volume excess (decongestion not achieved).
Time frame: within 3 days
NT pro BNP
the effect of adding combination oral acetazolamide on NT pro BNP levels in ADHF participants who received iv furosemide
Time frame: within 3 days
Renal Function
Kidney function is measured based on estimated GFR (eGFR) according to the CKD-EPI formula which is shown in units of mL/min/1.73 m2 taken on day 0, day 2, and day 4, every 48 hours during hospitalization (after receiving treatment).
Time frame: From date of randomization until the date of first documented worsening renal function (increased of creatinine serum level >50% of baseline creatinine) or date of death from any cause, evaluation every 48 hours or whichever came first, up to 90 days
Urinary Output
the amount of urine for 24 hours is measured from the time the patient arrives at the emergency room, a urinary catheter tube is installed, measured every 24 hours during hospital treatment.
Time frame: From date of randomization until participants discharge from hospital up to 7 days post discharge.
Length of Stay
Defined as the duration of the patient receiving treatment in hospital from the time admitted to the ER until the patient was discharged/discharged from the hospital, obtained as the date of discharge from the hospital minus the sampling date +1.
Time frame: From date of randomization until the date of first documented progression and discharge from hospital or date of death from any cause, whichever came first, assessed up to 30 days.
Plan to share: No — Currently, the decision regarding which Individual Participant Data (IPD) will be included for sharing is still under consideration. This undecided status is due to several key factors that require thorough evaluation
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Nov 2024, 7 months after the start.
Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 7 months is below that.
Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetazolamide
Universitas Diponegoro